The announcement follows similar moves by Novo Nordisk and Eli Lilly earlier this month
The treatment is already approved in the US for three disease states of prostate cancer
Included in the proposals are calls for a fixed rebate rate of 6.88% on all eligible NHS medicine sales to be paid by the industry
Both individuals and primary care physicians reported a reluctance to address cognitive concerns
21GRAMS takes four Golds plus Best in Show AstraZeneca tops the pharma leader board